295311-35-2

Upstream product

• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 295311-34-1 N-(5-amino-2-methylphenyl)-2-amino-5-(4-methylpiperazin-1-yl)-benzamide 
• 122-51-0 orthoformic acid triethyl ester 
• 295311-32-9 N-(2-methyl-5-nitrophenyl)-5-chloro-2-nitrobenzamide 
• 295311-52-3 2-amino-N-(5-amino-2-methylphenyl)-5-(4-methyl-1,4-diazepan-1-yl)benzamide 

Downstream Products

• 1383110-64-2 C₂₄H₂₄N₆O₂S 
• 1383110-70-0 C₂₅H₂₅N₅O₃ 
• 1383110-57-3 C₂₆H₂₆N₆O₂ 
• 1383110-67-5 C₂₄H₂₄N₆O₂S 
• 1383110-62-0 C₂₄H₂₄N₆O₂S 
• 1383110-49-3 C₂₆H₃₁N₅O₃ 
• 295310-31-5 3-[5-(2-Chloropyrid-4-ylcarbonylamino)-2-methylphenyl]-6-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one 
• 295310-21-3 3-[2-methyl-5-(2-pyrrolidin-1-ylpyrid-4-ylcarbonylamino)phenyl]-6-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one 
• 295310-57-5 C₃₁H₃₄N₆O₃ 
• 1383110-35-7 C₂₈H₂₉N₅O₃ 
• 1383110-39-1 C₂₈H₂₆N₆O₂ 
• 1383110-59-5 C₂₄H₂₄N₆O₃ 
• 1383110-54-0 C₂₄H₂₇N₅O₂ 
• 1383110-28-8 C₂₇H₂₇N₅O₂ 

Relevant academic research and scientific papers

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4- oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clinical candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin- 3(4H)-yl]benzamide (AZD6703). Optimisation was guided by understanding of the binding modes from X-ray crystallographic studies which showed a switch from DFG 'out' to DFG 'in' as the inhibitor size was reduced to improve overall properties.

SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

AMIDE DERIVATIVES

The invention concerns amide derivatives of Formula (Ia) wherein X is -NHCO- or -CONH-; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group